Point Of Care Hematology Diagnostics Market Report 2026

Point Of Care Hematology Diagnostics Market Overview

• Point Of Care Hematology Diagnostics market size has reached to $2.9 billion in 2025 • Expected to grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Increasing Prevalence Of Blood Disorders Fueling The Growth Of The Market Due To Rising Chronic Disease Incidence And Need For Timely Monitoring • Market Trend: Artificial Intelligence-Powered Cartridge System Transforms On-Site Blood Analysis • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Point Of Care Hematology Diagnostics Market?

Point of care hematology diagnostics refers to medical tests conducted at or near the site of patient care to quickly assess blood-related conditions, such as anemia, infections, or clotting disorders. These tests provide rapid, accurate hematological results to support timely clinical decisions, especially in emergency or resource-limited settings. This approach reduces the need for centralized laboratory testing and accelerates diagnosis and treatment. The main types of point-of-care hematology diagnostics are complete blood count, coagulation testing, hemoglobin testing, anemia diagnosis, and others. A complete blood count (CBC) is a blood test that measures various components of blood, including red blood cells, white blood cells, hemoglobin, hematocrit, and platelets, to help evaluate overall health and detect a wide range of disorders. These diagnostics are available in products as consumables and systems. The different modes of prescription include both prescription-based and over-the-counter-based products, catering to various end users such as diagnostic centers, hospitals, blood banks, transfusion centers, and others.

What Is The Point Of Care Hematology Diagnostics Market Growth Forecast?

The point of care hematology diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising prevalence of chronic and infectious diseases, expansion of point of care testing programs, increasing demand for rapid diagnostics in emergency care, technological advancements in compact hematology analyzers, growth in decentralized healthcare delivery models. Major trends in the forecast period include rising adoption of rapid bedside blood testing, growing demand for decentralized diagnostics in emergency settings, increasing use of portable and handheld hematology devices, expansion of point of care testing in resource-limited areas, focus on faster turnaround time for clinical decision-making.

Global Point Of Care Hematology Diagnostics Market Segmentation

1) By Type: Complete Blood Count, Coagulation Testing, Hemoglobin Testing, Anemia Diagnosis, Other Types 2) By Mode Of Prescription: Prescription Based Product, Over-The-Counter Based Product 3) By End User: Diagnostic Centers, Hospitals, Blood Banks, Transfusion Centers, Other End Users Subsegments: 1) By Complete Blood Count: White Blood Cell Count, Red Blood Cell Count, Platelet Count, Hematocrit, Hemoglobin Concentration, Mean Corpuscular Volume (MCV) 2) By Coagulation Testing: Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), International Normalized Ratio (INR), D-Dimer Test, Fibrinogen Level 3) By Hemoglobin Testing: Total Hemoglobin, Glycated Hemoglobin (HbA1c), Oxyhemoglobin, Carboxyhemoglobin, Methemoglobin 4) By Anemia Diagnosis: Iron Studies, Vitamin B12 Levels, Folate Levels, Reticulocyte Count, Ferritin Test, Transferrin Saturation 5) By Other Types: Blood Typing And Crossmatching, Erythrocyte Sedimentation Rate, Malaria Parasite Detection, Sickle Cell Screening, C-Reactive Protein Testing

What Is The Driver Of The Point Of Care Hematology Diagnostics Market?

The increasing prevalence of blood disorders is expected to propel the growth of the point-of-care hematology diagnostics market going forward. Blood disorders refer to conditions that affect the components of blood, including red blood cells, white blood cells, platelets, or plasma. The increasing incidence of blood disorders is primarily due to the rising prevalence of chronic diseases, which directly impact blood health and require ongoing monitoring. Point-of-care hematology diagnostics help in the timely detection and monitoring of blood disorders by providing rapid, accurate results at or near the site of patient care, enabling quicker clinical decisions and improved disease management.For instance, in November 2024, according to the The American Society of Hematology a US-based Non-profit organization, projected that global leukemia cases could increase to approximately 519,540 by 2050. Therefore, the rising incidence of blood disorders is driving the growth of the point-of-care hematology diagnostics market.

Key Players In The Global Point Of Care Hematology Diagnostics Market

Major companies operating in the point of care hematology diagnostics market are F. Hoffmann‑La Roche Ltd., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio‑Medical Electronics Co. Ltd., Sysmex Corporation, HORIBA Ltd., Nova Biomedical Corp., S.D. Sight Diagnostics Ltd., EKF Diagnostics Holdings plc., BioMedomics Inc., PixCell Medical Technologies Ltd., Boule Diagnostics AB, Nihon Kohden Corporation, Edan Instruments Inc., A Menarini Industrie Farmaceutiche Srl, Becton Dickinson and Company, Ortho Clinical Diagnostics, Khema Diagnostics, Bio‑Rad Laboratories Inc.

Global Point Of Care Hematology Diagnostics Market Trends and Insights

Major companies operating in the point-of-care hematology diagnostics market are focusing on developing technologically advanced products, such as cartridge-based AI-powered hematology analyzers, to deliver rapid, accurate, and on-site blood analysis for improved patient care. Cartridge-based AI-powered hematology analyzers are compact diagnostic devices that use single-use reagent cartridges and artificial intelligence algorithms to quickly and accurately analyze blood samples at the point of care. For instance, in September 2024, Zoetis Inc., a US-based veterinary health company, launched Vetscan OptiCell, a cartridge-based, AI-powered hematology analyzer designed for veterinary use. This innovative system delivers rapid, reference laboratory-quality complete blood count (CBC) results within minutes at the point of care, while reducing maintenance and hands-on time. It is equipped with advanced AI-driven image analysis and viscoelastic focusing technology that precisely aligns cells for clear imaging, enabling accurate blood cell classification and automated abnormality detection, thereby ensuring efficient and reliable veterinary diagnostics.

What Are Latest Mergers And Acquisitions In The Point Of Care Hematology Diagnostics Market?

In June 2023, Mars Inc., a US-based pet company, acquired Heska Corporation for an undisclosed amount. With this acquisition, Mars Inc. aims to expand its veterinary diagnostics capabilities and strengthen its position in advanced animal healthcare through Heska’s innovative diagnostic and specialty solutions. Heska Corporation is a US-based veterinary diagnostics company offering point-of-care (POC) hematology diagnostics.

Regional Outlook

North America was the largest region in the point of care hematology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Point Of Care Hematology Diagnostics Market?

The point of care hematology diagnostics market consists of revenues earned by entities by providing services such as rapid blood testing, decentralized diagnostic solutions, and home-based blood monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The point of care hematology diagnostics market also includes sales of portable hematology analyzers, cartridges and test kits, lancets, and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.